Nano-X Imaging Ltd. (NNOX) Latest Stock News & Headlines - Yahoo Finance
This Yahoo Finance article provides recent news and headlines related to Nano-X Imaging Ltd. (NNOX), detailing company announcements such as the scheduling of third-quarter 2026 financial results, plans to showcase innovative technology at RSNA 2026, and several distribution agreements for its AI solutions in various markets. The company is also implementing cost reduction measures and expanding collaborations, reflecting its ongoing efforts to advance medical imaging access and technology.
Nanox to Showcase Its Innovative Technology and Advances Across Nanox.ARC X and Nanox.AI at RSNA 2026
Nanox announced it will exhibit its Nanox.ARC X imaging system and Nanox.AI software at the Radiological Society of North America (RSNA) 2026 meeting in Chicago from November 29 to December 2. The company will conduct live demonstrations and host presentations by its CEO and on aortic valve calcification AI. While Nanox.ARC X and Nanox.AI are FDA-cleared, several new features previewed are still under development and not yet approved for clinical use.
Nanox to Showcase Its Innovative Technology and Advances Across Nanox.ARC X and Nanox.AI at RSNA 2026
Nanox announced it will exhibit at the Radiological Society of North America (RSNA) 2026 meeting in Chicago, demonstrating its FDA-cleared Nanox.ARC X imaging system and Nanox.AI software. The company will also host two theater presentations, one by its CEO and another on aortic valve calcification AI. While some features are FDA-cleared, several advanced features, including pediatric imaging and Mobile Nanox.ARC, are still under development and not yet approved for clinical use.
Nanox to Report Third Quarter 2026 Financial Results on November 25, 2026
NANO-X IMAGING LTD (Nanox) announced it will report its financial results for the quarter ended September 30, 2026, before market open on Wednesday, November 25, 2026. CEO Erez Meltzer will host a conference call at 8:30 a.m. ET to review these results and provide a business update. Nanox, a leader in innovative medical imaging technology, is focused on advancing preventive health care through an integrated medical imaging and healthcare services platform.
Nanox to Report Third Quarter 2026 Financial Results on November 25, 2026
NANO-X IMAGING LTD (Nasdaq: NNOX) announced that it will report its financial results for the quarter ended September 30, 2026, before market open on Wednesday, November 25, 2026. CEO Erez Meltzer will host a conference call at 8:30 a.m. ET to discuss these results and provide a business update. Interested parties can register for the call or access the live webcast via links provided on the Nanox website.
A Greek reseller will offer Nanox's AI bone solution to healthcare providers
Nanox Imaging has signed a non-exclusive distribution agreement with Medworks to expand the commercial reach of its Nanox.AI HealthOST solution in Greece. Medworks will initially resell HealthOST, Nanox.AI’s FDA-cleared and CE-marked AI-based bone solution, leveraging its established presence and experience with Greek healthcare providers. This partnership builds on Nanox.AI's existing deployment in Athens and aims to support broader commercial expansion in the country.
Nanox Announces Distribution Agreement with Medworks for Nanox.AI in Greece
Nanox Imaging Ltd. has signed a non-exclusive distribution agreement with Medworks LTD to expand the commercial presence of its Nanox.AI’s HealthOST solution in Greece. Medworks will leverage its established market presence and experience in medical imaging technologies to support the adoption of Nanox.AI, building on its existing deployment in Athens. This partnership aims to enhance access to Nanox.AI and strengthen the company's footprint in the Greek healthcare market.
Form 13D/A Nano-X Imaging Ltd. For: 12 November By Investing.com
This article announces the filing of Form 13D/A by Nano-X Imaging Ltd. on November 12. The filing is a regulatory disclosure related to significant ownership stakes in a public company. The article provides the title and date of the filing, along with the associated stock symbol NNOX.
Two directors join Nano-X Imaging (NNOX) as its CEO steps down as chairman.
Nano-X Imaging Ltd. has appointed Jonathan Samet and Ariel Katz to its board of directors, following an agreement with entrepreneur and investor Moshe Moalem. Erez Meltzer has resigned as Chairman but will continue as CEO and a director, with Erez Alroy elected as the new Chairman. This restructuring is part of a Board Nomination Agreement that includes voting commitments from Moalem for a reverse-split and increased authorized capital proposals.
Nano-X Imaging Stock Rebounds From Record Low: What’s Driving the Move?
Shares of Nano-X Imaging Ltd (NASDAQ: NNOX) are trading higher after its subsidiary, Nanox.AI, announced a commercial collaboration with Dosy Health to support the planned commercialization of its CT-based cardiac solution in Thailand. This agreement comes as Nano-X is implementing a plan to cut annualized operating expenses by 25% to 30% by the end of Q1 2027. The stock rebounded significantly from an all-time low.
12 Health Care Stocks Moving In Tuesday's Intraday Session
This article lists twelve healthcare stocks that experienced significant price movements during Tuesday's intraday trading session. Six stocks, including PepGen and Nano X Imaging, saw gains, with several attributing their rise to recent Q3 earnings reports. Conversely, six other stocks, such as Karyopharm Therapeutics and Exagen, experienced declines, also influenced by Q3 earnings announcements.
Nanox.AI signs distribution deal with Dosy Health for Thailand cardiac AI
Nanox.AI, a subsidiary of Nano-X Imaging Ltd. (NASDAQ: NNOX), has entered a distribution agreement with Dosy Health, a Thai healthcare technology company. This deal aims to commercialize Nanox.AI's CT-based cardiac imaging software, HealthCCSng, in Thailand, pending regulatory approvals. The collaboration leverages Dosy Health's existing relationships with major universities and hospitals to introduce the cardiac solution to the Thai market.
Nanox.AI signs distribution deal for cardiac imaging in Thailand By Investing.com
Nano-X Imaging Ltd. (NASDAQ:NNOX) subsidiary Nanox.AI has signed a distribution agreement with Dosy Health, a Thai healthcare technology company, to introduce and commercialize its HealthCCSng cardiac imaging solution in Thailand. This CT-based solution provides coronary artery calcium measurements from routine scans. The partnership aims to leverage Thailand's extensive CT scanner base, with potential expansion into bone and liver imaging.
Several Thai hospitals expressed preliminary interest in AI heart-scan analysis, Dosy says.
Nano-X Imaging's subsidiary, Nanox.AI, has signed a distribution agreement with Dosy Health to introduce its HealthCCSng cardiac solution in Thailand. This AI-powered solution analyzes existing CT scans to provide coronary artery calcium measurements for clinicians. The collaboration leverages Dosy's relationships with major Thai universities and hospitals, with several hospitals already expressing preliminary interest, though no purchase commitments have been made yet.
Form 6-K Nano-X Imaging Ltd. For: Nov 09
NANO-X IMAGING LTD filed a Form 6-K announcing a strategic realignment and efficiency plan approved by its Board of Directors on November 9, 2026. This plan aims to reduce GAAP and non-GAAP operating expenses by 25%-30% compared to annualized 2026 expenses, through measures including workforce reductions and operational adjustments. The company will also focus on four strategic priorities, including accelerating U.S. commercialization of Nanox.ARC and Nanox Imaging Network, strengthening commercial partnerships, improving operational efficiency, and enhancing financial flexibility.
Nanox.AI Advances Commercial Collaboration with Dosy Health to Bring AI Cardiac Solution to Thailand
Nanox.AI, a subsidiary of Nano-X Imaging, has signed a distribution agreement with Thailand-based Dosy Health to introduce its HealthCCSng cardiac CT AI solution in Thailand. This collaboration is an early market-expansion step, with preliminary hospital interest noted, though no purchase commitments or financial terms have been disclosed yet. The HealthCCSng solution analyzes routine non-contrast, non-gated CT scans to provide coronary artery calcium measurements.
Nanox Announces That Board Has Approved Cost Reduction and Operational Efficiency Measures
Nanox's board has approved a plan to cut annualized operating expenses by 25%-30% by the end of Q1 2027, which includes a workforce reduction and builds on earlier South Korea operations restructuring. While these measures aim to extend cash resources and reduce cash burn, the company still anticipates needing additional financing, which may not be available on acceptable terms. The company acknowledges potential near-term increases in cash outflows due to restructuring payments and has recurring operating losses, raising substantial doubt about its ability to continue as a going concern.
Nanox.AI Advances Commercial Collaboration with Dosy Health to Bring AI Cardiac Solution to Thailand
Nanox.AI, a subsidiary of Nano-X Imaging, has signed a distribution agreement with Thailand-based Dosy Health to introduce its HealthCCSng cardiac AI solution. This collaboration aims to bring CT-based cardiac analysis to Thailand, with Dosy Health reporting preliminary interest from several hospitals. While this marks an early market expansion step, discussions with hospitals are still preliminary and no purchase commitments or financial terms have been disclosed.
Nanox board approves plan to cut operating expenses by up to 30%
Nano-X Imaging Ltd (NNOX) announced its board approved a plan to reduce annualized GAAP and non-GAAP operating expenses by 25-30% compared to 2026 levels, excluding one-time restructuring charges. This initiative includes global workforce reductions and other operational adjustments, aiming to extend cash resources and decrease ongoing cash burn. The company also outlined four strategic priorities and is exploring financing alternatives and potential divestitures to address liquidity concerns and Nasdaq compliance.
Nanox Announces That Board Has Approved Cost Reduction and Operational Efficiency Measures
NANO-X IMAGING LTD (NASDAQ: NNOX) announced that its Board of Directors has approved a plan to reduce costs and improve operational efficiency. This plan, which includes workforce reductions and other operational adjustments, aims for a 25%-30% reduction in annualized operating expenses by the end of Q1 2027. The company intends to focus on accelerating commercialization of Nanox.ARC and Nanox Imaging Network, strengthening commercial partnerships, improving operational efficiency, and enhancing financial flexibility.
USARAD, a Nanox Company, Expands Collaboration with AZmed to Integrate FDA-Cleared X-ray AI into Its Teleradiology Workflows
USARAD, a subsidiary of Nanox Imaging, is expanding its collaboration with AZmed to integrate AZmed's FDA-cleared X-ray AI suite into its radiology workflows. This partnership aims to enhance efficiency for radiologists by helping them prioritize and read studies more effectively. The expanded agreement will see USARAD utilizing AZmed's AZtrauma, AZchest, and Rayvolve LN tools, all of which are FDA-cleared, for various X-ray findings.
USARAD, a Nanox Company, Expands Collaboration with AZmed to Integrate FDA-Cleared X-ray AI into Its Teleradiology Workflows
USARAD, a subsidiary of Nanox, is expanding its collaboration with AZmed to integrate AZmed's FDA-cleared X-ray AI suite into USARAD's radiology workflows. This partnership aims to enhance efficiency for radiologists in prioritizing and interpreting medical images. While the agreement deepens an existing relationship, no financial terms or revenue figures for the expanded deal were disclosed.
USARAD, a Nanox Company, Expands Collaboration with AZmed to Integrate FDA-Cleared X-ray AI into Its Teleradiology Workflows
USARAD Holdings, Inc., a wholly-owned subsidiary of Nanox Imaging Ltd., has announced an expanded collaboration with AZmed to further integrate AZmed's FDA-cleared X-ray AI solutions into USARAD's radiology workflows. This expansion builds on USARAD's existing use of AZmed's AI, including AZtrauma for musculoskeletal trauma and AZchest for chest X-rays, to enhance efficiency in prioritizing and reading studies. The integration will occur through Nanox Marketplace, facilitating automated study routing and DICOM transmission, allowing radiologists to access AI results within their existing OnePacs platform.
TCT 2026 Clinical Data Reveals 84% Reporting Gap in Aortic Valve Calcification, Highlighting the Potential of Nanox.AI’s AVC Solution
Nanox Imaging Ltd. announced updated clinical data from the TCT 2026 Conference revealing an 84% reporting gap in aortic valve calcification (AVC) in routine radiology reports. The company's investigational Nanox.AI HealthAVC solution demonstrated high sensitivity and specificity in identifying previously unreported AVC on CT scans, suggesting AI's potential to improve detection and lead to earlier cardiovascular evaluation for at-risk patients. The HealthAVC solution is currently under development and not yet cleared for clinical use.
TCT 2026 Clinical Data Reveals 84% Reporting Gap in Aortic Valve Calcification, Highlighting the Potential of Nanox.AI’s AVC Solution
New clinical data presented at TCT 2026 revealed an 84% reporting gap in aortic valve calcification (AVC) in routine radiology reports, highlighting a significant overlooked population at risk for severe aortic stenosis. Nanox Imaging Ltd.'s Nanox.AI solution demonstrated high sensitivity and specificity in detecting previously unreported AVC in evaluable CT scans. This suggests AI-based tools could significantly improve early identification of patients who might benefit from further cardiovascular evaluation.
In 84% of CT scans with confirmed aortic valve calcium, radiology reports didn't mention it.
A Nanox Imaging (NASDAQ: NNOX) study presented at TCT 2026 revealed that 84.3% of CT scans with manually confirmed aortic valve calcification (AVC) did not explicitly mention it in original radiology reports. Nanox.AI’s HealthAVC solution, still under development, demonstrated 98.3% sensitivity and 96.6% specificity in evaluable scans, detecting 142 out of 145 undocumented cases. This highlights a significant reporting gap and the potential of AI to improve early identification of patients at risk for severe aortic stenosis.
Moshe Moalem Pushes for Changes at Nano-X Imaging with 8.49% Stake
Moshe Moalem, an entrepreneur and investor, has disclosed an 8.49% stake in Nano-X Imaging Ltd. and intends to push for changes, including opposing a proposed share authorization increase that he believes could dilute existing shareholders. Moalem plans to discuss business strategy, financial performance, and governance with management and the board, and may consider legal action or propose board changes to protect shareholder rights. He filed a Schedule 13D on October 29, 2026, ahead of the company's special shareholder meeting on November 18.
NANO-X IMAGING LTD Estimates – NASDAQ:NNOX
The article provides an overview of NANO-X IMAGING LTD (NASDAQ: NNOX) financials on TradingView, covering reported financial data and analyst estimates across income statements, balance sheets, cash flow, and valuation metrics. It allows users to compare actual results with average, high, and low estimates and visualize trends over time. The content emphasizes that it is not investment advice and encourages users to conduct their own research.
Nano-X Imaging (NASDAQ: NNOX) Advances Its Mission to Expand Access to Medical Imaging
Nano-X Imaging (NASDAQ: NNOX) is working to enhance access to medical imaging through its digital 3D tomosynthesis technology and Nanox.ARC platform. The company aims to make advanced imaging more available in underserved regions and outpatient facilities, addressing challenges like limited equipment, infrastructure, and personnel. By integrating imaging hardware with cloud-based infrastructure and AI-powered analysis, Nanox seeks to improve diagnostic services and support healthcare providers.
Form 4 Nano-X Imaging Ltd.: Erez Meltzer (Director, CEO) For: 19 October
This article from Investing.com reports on a Form 4 filing for Nano-X Imaging Ltd., indicating that Erez Meltzer, identified as both a Director and CEO, was involved in a transaction on October 19th. The Form 4 is a document required by the SEC to be filed by company insiders when they buy or sell shares of their company's stock. The article provides the basic announcement without further details on the nature of the transaction.
Form 4 Nano-X Imaging Ltd.: Erez Meltzer (Director, CEO) For: 19 October
This article reports on a Form 4 filing for Nano-X Imaging Ltd. (NNOX), detailing insider transactions by Erez Meltzer, who serves as both a Director and CEO of the company. The filing specifically pertains to activity that occurred on October 19th. The article notes the company's stock symbol and a recent price increase.
Through his wholly owned company, Nano-X Imaging (NNOX) CEO buys 25,000 shares at $0.45.
Nano-X Imaging Ltd. CEO and director Erez Meltzer indirectly purchased 25,000 ordinary shares of NNOX at $0.45 per share on October 19, 2026, through his wholly owned company, Oud Nof. Following this transaction, Oud Nof holds 90,443 shares. Meltzer also holds 60,584 direct ordinary shares and three direct option positions, with one tranche of options scheduled to be fully vested by April 16, 2028.
Nano-X Imaging Ltd. (NNOX) Signs Deal to Distribute HealthOST in Italy
Nano-X Imaging Ltd. (NNOX) has signed a distribution agreement through its subsidiary Nanox AI Ltd. with Technologic s.r.l. to commercialize its HealthOST AI bone health solution in Italy. This deal represents an early-stage commercial expansion into the Italian market, targeting osteoporosis assessment via CT scans. The success of this agreement will depend on customer acquisition, deployment volumes, and future revenue generation.
Nano-X Imaging (NASDAQ: NNOX) Subsidiary Signs Distribution Agreement to Commercialize HealthOST in Italy
Nanox AI Ltd., a subsidiary of Nano-X Imaging (NASDAQ: NNOX), has partnered with Technologic s.r.l. to distribute its AI-powered bone health solution, HealthOST, in Italy. This agreement aims to expand Nanox AI's commercial presence in the Italian market and leverage Technologic's local expertise. HealthOST helps clinicians identify patients at risk for musculoskeletal conditions like osteoporosis by analyzing routine CT scans.
Nano-X Imaging Ltd. (NNOX) Signs Italy Distribution Deal for HealthOST
Nano-X Imaging Ltd. announced that its subsidiary, Nanox AI Ltd., has signed a distribution agreement with Technologic s.r.l. to commercialize its HealthOST AI bone health solution in Italy. This agreement marks an early-stage commercial expansion for Nanox AI, aiming to extend its footprint in Europe and address the clinical need for osteoporosis assessment via CT scans. The success of this deal will depend on customer acquisitions, deployment volumes, and revenue generation.
Form 4 Nano-X Imaging Ltd.: James Dara (GM Source & Services Division) For: 11 October
This article reports on a Form 4 filing for Nano-X Imaging Ltd., specifically concerning James Dara, the GM of the Source & Services Division, for activity on October 11. The piece from Investing.com is concise, simply stating the filing without providing further details or analysis of the transaction itself. It is embedded within a financial news portal, offering various market data and other news.
NNOX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Nano-X Imaging Ltd. Investors Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Nano-X Imaging Ltd. (NASDAQ: NNOX) and certain officers. The lawsuit, filed on behalf of investors who purchased Nano-X securities between March 31, 2025, and April 17, 2026, alleges that the company made false and misleading statements regarding its operations and demand for its products, leading to increased operating expenses and potential restructuring. Investors who suffered losses have until August 11, 2026, to request to be appointed as lead plaintiff.
Nanox reports preliminary Q3 revenue up to $4.4 million
Nano-X Imaging Ltd (NNOX) announced preliminary unaudited Q3 revenue of $4.3 million to $4.4 million, an increase from $3.4 million in the prior year. While teleradiology services remained flat, AI and software solutions revenue saw significant growth due to the consolidation of Nanox Health IT Inc. However, the company also expressed substantial doubt about its ability to continue as a going concern, noting that its cash and deposits are not sufficient to support operations for at least one year.
Nanox Provides Business Update and Furnishes Certain Preliminary Unaudited Financial Data for Third Quarter Ended September 30, 2026
Nanox (NASDAQ: NNOX) provided a business update and preliminary unaudited financial data for the third quarter ended September 30, 2026. Key highlights include a distribution agreement for Nanox.AI’s Bone Solution in Italy and recognition as one of TIME’s Best Inventions of 2026 for its Nanox.ARC X. The company reported preliminary revenues of $4.3 to $4.4 million, up from $3.4 million in the comparable period of 2025, but noted that its cash and cash equivalents are not sufficient to support operations for at least one year, raising substantial doubt about its ability to continue as a going concern.
Nanox.AI signs distribution deal for bone health software in Italy
Nanox AI Ltd., a subsidiary of Nano-X Imaging Ltd. (NASDAQ: NNOX), has secured a distribution agreement with Technologic s.r.l. to commercialize its HealthOST bone health software in Italy. HealthOST analyzes routine CT scans for musculoskeletal diseases like osteoporosis. This partnership expands Nanox.AI's reach into the Italian market, leveraging Technologic s.r.l.'s established presence in medical technology.
Nanox.AI signs distribution deal for bone health software in Italy
Nanox AI Ltd., a subsidiary of Nano-X Imaging Ltd. (NASDAQ:NNOX), has signed a distribution agreement with Technologic s.r.l. to bring its HealthOST bone solution to the Italian market. HealthOST is an AI-powered software designed to analyze routine CT scans for early detection and assessment of musculoskeletal diseases like osteoporosis. This collaboration expands Nanox.AI's global reach and Technologic s.r.l.'s offering of advanced solutions to healthcare professionals.
Nano-X Imaging unit signs Italy distribution deal for bone health AI tool
Nano-X Imaging Ltd.'s subsidiary, Nanox AI Ltd., has signed a distribution agreement with Technologic s.r.l. to commercialize its AI-based bone health product, HealthOST, in Italy. HealthOST analyzes routine CT scans to assess musculoskeletal conditions like osteoporosis, helping clinicians identify patients needing further evaluation. This partnership expands Nano-X's global reach for advanced bone health assessment solutions.
Nanox AI Ltd. Enters into Distribution Agreement with Technologic s.r.l., an Affiliate of Tecnologie Avanzate, to Commercialize Nanox.AI Bone Solution in Italy
Nanox AI Ltd. has signed a distribution agreement with Technologic s.r.l., an affiliate of Tecnologie Avanzate, to commercialize its Nanox.AI Bone Solution (HealthOST) in Italy. This collaboration leverages Tecnologie Avanzate's extensive experience in the Italian medical technology market to expand the reach of Nanox.AI's AI-powered bone health assessment solution. HealthOST aims to assist clinicians in identifying early signs of musculoskeletal diseases like osteoporosis from routine CT scans, promoting proactive patient care.
A tool uses scans already taken for care to assess bone health. Nanox AI signs an Italy deal.
Nanox AI, a subsidiary of Nano-X Imaging (NASDAQ: NNOX), has signed a distribution agreement with Technologic s.r.l. to commercialize its HealthOST bone solution in Italy. HealthOST analyzes routine CT scans to assess musculoskeletal diseases like osteoporosis, aiming to provide earlier detection and intervention. This collaboration leverages Tecnologie Avanzate's extensive experience in the Italian medical technology market to expand Nanox.AI's commercial reach.
Nanox Selected as One of TIME’s Best Inventions of 2026 for its Nanox.ARC X
Nanox Imaging Ltd. announced that its Nanox.ARC X system has been recognized as one of TIME’s Best Inventions of 2026, marking its second appearance on the list. The Nanox.ARC X is an FDA-cleared digital tomosynthesis system designed to make advanced medical imaging more accessible by providing 3D views with significantly less radiation than CT scans, using standard power, and having a reduced physical footprint. This award acknowledges Nanox's commitment to innovation and expanding access to preventive healthcare globally.
Nanox Selected as One of TIME’s Best Inventions of 2026 for its Nanox.ARC X
Nanox Imaging Ltd. (NASDAQ: NNOX) announced that its Nanox.ARC X system has been selected as one of TIME’s Best Inventions of 2026 for its role in making advanced medical imaging more accessible. This marks Nanox's second appearance on TIME's list, recognizing the FDA-cleared digital tomosynthesis system's ability to produce 3D X-ray views with significantly reduced radiation and its ease of deployment in various healthcare settings. The company aims to drive preventive healthcare by integrating affordable imaging hardware, AI solutions, and cloud-based platforms to improve early detection and patient outcomes.
TIME picks an X-ray system that makes 3D views with up to 80% less radiation than CT for the same body parts.
Nanox Imaging (NNOX) announced that its Nanox.ARC X medical imaging system has been selected for TIME's Best Inventions of 2026 list, marking the company's second appearance on the list. The Nanox.ARC X is an FDA-cleared digital tomosynthesis system that provides 3D views with up to 80% less radiation than CT scans for equivalent body parts. This recognition highlights Nanox's commitment to making advanced medical imaging more accessible globally.
Form 4 Nano-X Imaging Ltd.: Feler Marina Gofman (CLO) For: 13 October
This article announces that Nano-X Imaging Ltd. (NNOX) has filed a Form 4 regarding Feler Marina Gofman (CLO) for October 13. The Form 4 is a document used to disclose transactions by company insiders. The brief piece provides no further details beyond this announcement.
A 28,283-share award at Nano-X Imaging (NNOX) vests in four 25% installments, subject to employment.
Nano-X Imaging Ltd. granted Chief Corporate Resources Attias Gali Yahav 28,283 restricted share units (RSUs) on October 14, 2026. These RSUs will vest in four equal semi-annual installments of 25% each, starting February 13, 2027, and concluding August 13, 2028, contingent upon his continuous employment. Yahav also holds several options for ordinary shares with various exercise prices and expiration dates, some of which are already fully vested.
CFO Guy Nathansohn receives a 50,000-share stock grant from Nano-X Imaging (NNOX).
Nano-X Imaging Ltd. (NNOX) has granted its CFO, Guy Nathansohn, 50,000 restricted share units (RSUs). These RSUs are scheduled to vest in two equal installments on October 14, 2027, and October 14, 2028, contingent upon his continuous employment. An additional informational entry notes a previous grant of 50,000 RSUs on July 15, 2026, with similar vesting conditions.